Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX008 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Subjects will be dosed weekly during each 21-day cycle. Dosage per cohort will increase to determine the maximum tolerable dose. |
| Backfill Expansion | EXPERIMENTAL | Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at levels previously declared tolerable. |
| Expansion | EXPERIMENTAL | Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at the preliminary recommended Phase 2 dose (RP2D). |
| Name | Type | Description |
|---|---|---|
| JANX008 | DRUG | JANX008 is dosed via IV weekly in a 21-day cycle |
Inclusion Criteria: * Subjects ≥18 years of age at the time of signing informed consent * Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, RCC, SCLC, PDAC, TNBC * Progressed or was intolerant to all available therapies known to confer clinical benefit app...
Top 20 of 84 competitors
JANX008 is an investigational small molecule being developed for Non-Small Cell Lung Cancer. It is also being studied in other advanced or metastatic solid tumor malignancies, including renal cell carcinoma, squamous cell carcinoma of the head and neck, colorectal carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
JANX008 targets EGFR, the epidermal growth factor receptor. By targeting EGFR, the drug is designed to interfere with signaling pathways that can drive tumor growth in certain cancers, including Non-Small Cell Lung Cancer.
JANX008 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol JANX. The company is conducting clinical research on this investigational drug for oncology indications.
JANX008 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated for safety and efficacy in clinical trials.
JANX008 is being studied in a Phase 1 clinical trial with the identifier NCT05783622, titled "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies." The trial is active but not recruiting, with an estimated enrollment of 130 participants in the United States.
No alternative names for JANX008 have been disclosed. The drug is identified by its code name JANX008 in clinical trial registries and by its developer, Janux Therapeutics, Inc.